Moscow. On 6 November. Anglo-Swedish pharmaceutical company AstraZeneca has signed a binding agreement to acquire American biotechnology firm ZS Pharma for about $2.7 billion
As reported in a press release, AstraZeneca, she’ll pay $90 for each share of ZS Pharma. This is 42% higher than the level of quotations at the close of the market on Thursday.
The Board of Directors at ZS Pharma unanimously approved the terms of the agreement with the British company.
After the completion of the transaction ZS Pharma, which employs about 200 people at three facilities in California, Texas and Colorado, will become a 100% unit of AstraZeneca.
The transaction is expected to be completed until the end of 2015, the report says.
Share prices of AstraZeneca in early trading on Friday increased by 0.05%.